Volastra Therapeutics
Small molecule therapeutics for inflammatory and fibrotic diseases
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2019
- Latest Form D
- $30.1M, Sep 2025
- Total capital
- $105M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $105M
- 3 Form D · last Sep 2025
- 13 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 37 pending · first 2023
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$30.1M
- Private capital raisedForm D · SEC · 2nd filing$15M
- Private capital raisedForm D · SEC · 1st filing$60.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amy SchulmanDirectorNamed in SEC Form D filings
- Arjun Zolot BalarDirectorNamed in SEC Form D filings
- Charles Hugh-JonesExecutive Officer, DirectorNamed in SEC Form D filings
- David NicholsonDirectorNamed in SEC Form D filings
- David SouthwellExecutive Officer, DirectorNamed in SEC Form D filings
- Diane TagerExecutive OfficerNamed in SEC Form D filings
Show all 18 people
- Eileen Zolot McGuireDirectorNamed in SEC Form D filings
- Ellie McGuireDirectorNamed in SEC Form D filings
- Jill GoldsteinDirectorNamed in SEC Form D filings
- Luc DochezDirectorNamed in SEC Form D filings
- Michael SuExecutive OfficerNamed in SEC Form D filings
- Rachel Zolot SchwartzExecutive OfficerNamed in SEC Form D filings
- Rez Zolot HalzeDirectorNamed in SEC Form D filings
- Robert MittendorffDirectorNamed in SEC Form D filings
- Samuel Zolot BakhoumDirectorNamed in SEC Form D filings
- Sandra PetersonExecutive Officer, DirectorNamed in SEC Form D filings
- Scott DrutmanExecutive OfficerNamed in SEC Form D filings
- Stefan VitorovicDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 40- PendingHeterocyclic Inhibitors Of ENPP1USPTOApplication 19066119
- PendingSystems And Methods For Evaluation Of Mitotic Events Using Machine-learningUSPTOApplication 18693483
- PendingHeterocyclic Inhibitors Of ENPP1USPTOApplication 18771822
Show all 40 patent records
- Heterocyclic Inhibitors Of ENPP1Dec 4, 2025 · Application 19066119Pending
- Systems And Methods For Evaluation Of Mitotic Events Using Machine-learningDec 26, 2024 · Application 18693483Pending
- Heterocyclic Inhibitors Of ENPP1Nov 14, 2024 · Application 18771822Pending
- Indoline Compounds For Inhibiting KIF18AOct 24, 2024 · Application 18735162Pending
- Heterocyclic Inhibitors Of ENPP1Sep 17, 2024 · US 12,091,412Granted
- Indoline Compounds For Inhibiting KIF18ASep 10, 2024 · US 12,084,420Granted
- Compounds For Inhibiting KIF18ANov 30, 2023 · Application 18140533Pending
- Imino Sulfanone Inhibitors Of ENPP1Oct 10, 2023 · US 11,780,849Granted
- Method Of Treating Cancer With Indoline Inhibitors Of KIF18AApplication 63508233Pending
- Compounds For Inhibiting KIF18AApplication PCTUS2023020268Pending
- Compounds For Inhibiting KIF18AApplication 63456342Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication 63486611Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication 63486613Pending
- Tricyclic Sulfoximine Inhibitors Of ENPP1Application PCTUS2022078603Pending
- Systems And Methods For Evaluation Of Mitotic Events Using Machine-learningApplication PCTUS2022044287Pending
- Systems And Methods For Evaluation Of Mitotic Events Using Machine-learningApplication 63402854Pending
- Indoline Inhibitors Of KIF18AApplication PCTUS2022075472Pending
- Compounds For Inhibiting KIF18AApplication 63389237Pending
- ANTI-ENPP1 Antibodies And Uses ThereofApplication PCTUS2022035335Pending
- Indoline Inhibitors Of KIF18AApplication 63344435Pending
- Aryl INDOL-3-YL Ketone And Aryl INDAZOL-3-YL Ketone Inhibitors Of KIF18AApplication 19497220Pending
- Method Of Treating Cancer With Indoline Inhibitors Of KIF18AApplication 19492992Pending
- Compounds For Inhibiting KIF18AApplication 63336183Pending
- Indoline Inhibitors Of KIF18AApplication 63306452Pending
- Tricyclic Sulfoximine Inhibitors Of ENPP1Application 63271688Pending
- Systems And Methods For Evaluation Of Mitotic Events Using Machine-learningApplication 63247158Pending
- Indoline Inhibitors Of KIF18AApplication 63237275Pending
- ANTI-ENPP1 Antibodies And Uses ThereofApplication 63216428Pending
- Heterocyclic Inhibitors Of ENPP1Application PCTUS2021037496Pending
- Imino Sulfanone Inhibitors Of ENPP1Application PCTUS2021030496Pending
- Heterocyclic Inhibitors Of ENPP1Application 63132322Pending
- Imino Sulfanone Inhibitors Of ENPP1Application 63093709Pending
- Heterocyclic Inhibitors Of ENPP1Application 63039923Pending
- Imino Sulfanone Inhibitors Of ENPP1Application 63019853Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication 19157226Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication 19580267Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication PCTUS2024052612Pending
- Aryl INDOL-3-YL Ketone And Aryl INDAZOL-3-YL Ketone Inhibitors Of KIF18AApplication PCTUS2024036249Pending
- Method Of Treating Cancer With Indoline Inhibitors Of KIF18AApplication PCTUS2024033876Pending
- Solid Formulations And Polymorphic Forms Of Indoline Inhibitors Of KIF18AApplication PCTUS2024016952Pending
Related companies, and why
- OncoSpherix, Inc.Similar federal contract value in Biotech · null in contracts
- iECURESimilar federal contract value in Biotech · null in contracts
- Pathos AI, Inc.Similar federal contract value in Biotech · null in contracts
- Eyconis, Inc.Similar federal contract value in Biotech · null in contracts
- Eikon TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Perspective Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .